Corporate News

Hengchuang Frontier・Sai Leads Health | Grand Opening Ceremony of Hengsai Bio-Linkport R&D and Production Base
August 22, 2025 44
On August 15, 2025, the opening ceremony of the R&D and production base of Hengsai Biologicals in Lingang was held grandly in the 10th phase of Life Blue Bay Intelligence Park in Lingang New Area. With the theme of "Hengchuang Frontier, Sai Leads Health", the ceremony invited the Lingang Administrative Committee, industry experts, shareholders' representatives, partners, leaders of the park and all the staff of Hengsai Biologicals to witness this important moment together. Har...
View details
2025 EHA: Henselbio's KSD-101 DC Vaccine Breakthrough Data Unveiled, Expanding New Boundaries for EBV Hematoma Treatment
June 17, 2025 185
Hengsai BioItaly - Milan The 30th Annual Meeting of the European Hematology Association (EHA 2025) was successfully concluded from June 12 to 15 in Milan, Italy. As a global top event in the field of hematology, EHA gathered the world's top experts, scholars and industrial pioneers to discuss the latest breakthroughs and future direction of blood disease diagnosis and treatment. In this international academic feast, Hengsai Biotechnology, as one of the...
View details
2025 Annual Meeting and Spring Reunion Special Hengsai Biology
April 25, 2025 351
The snake offered a new chapter, and the elites went to the spring banquet together. At the time when the snake is coiled up and everything is new, all the staff of Hengsai Bio-technology gathered together and held the 2025 Annual Meeting and Annual Summarization Activity in Zhoushan, Zhejiang Province. The team of Hengsai traveled on the waves, refined tacit understanding with collaboration, and cohesion of consensus with laughter, and drew the prelude of the New Year together among the blue sea and golden sand. Breaking through ten thousand hectares of waves, the team went on a journey to the blue sea...
View details
Hengsai Bio DC Vaccine for Kidney Cancer Program Officially Launched
March 4, 2025 346
On March 3, 2025, Hengsai Bio's self-developed KSD-201 DC vaccine for advanced renal cell carcinoma was officially launched at Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology ("Wuhan Tongji Hospital").
View details
DC Vaccine for Nasopharyngeal Carcinoma [Medium Swelling] Completes First Patient Enrollment for Dosing
November 12, 2024 608
DC Vaccine for Nasopharyngeal Carcinoma [Medium Swelling] Completes First Patient Enrollment for Dosing
View details
Hengsai Biotechnology Wins the 13th China Innovation and Entrepreneurship Competition (Guangdong Region)
November 4, 2024 398
Hengsai Biotechnology Wins the 13th China Innovation and Entrepreneurship Competition (Guangdong Region)
View details
Hengsai Bio Zhongshan R&D Center Opens
October 28, 2024 512
Hengsai Bio Zhongshan R&D Center Opens
View details
Kousai Biological Dendritic Cell Vaccine Drug Production and Research Project Groundbreaking Ceremony Successfully Held
August 14, 2024 481
Kousai Biological Dendritic Cell Vaccine Drug Production and Research Project Groundbreaking Ceremony Successfully Held
View details
Exploring the Mystery of EBV and Tumor 丨Hengsai Biotechnology Shows Its Elegance on the International Academic Stage Again
July 19, 2024 362
Exploring the Mystery of EBV and Tumor 丨Hengsai Biotechnology Shows Its Elegance on the International Academic Stage Again
View details
2024 EHA | Prof. Chunrui Li: Focusing on China's original research power, the field of EBV-associated hematological oncology therapeutics is revitalized
June 21, 2024 279
2024 EHA | Prof. Chunrui Li: Focusing on China's original research power, the field of EBV-associated hematological oncology therapeutics is revitalized
View details

Expand more!